Semaglutide Pen from Hilma Biocare has become a real breakthrough in the pharmacotherapy of obesity. It is the first drug that has shown a sustained and significant reduction in body weight in overweight people in large clinical trials — without the need for surgery. In an international study, patients taking semaglutide lost an average of up to 15% of their initial body weight, on a standard diet and with moderate exercise. In comparison, the placebo group lost no more than 2-3%. Today, this drug has also become available to a wide range of patients.
Semaglutide acts through the incretin pathway – like GLP-1, it affects the receptors of the hormone glucagon. It suppresses the secretion of glucagon by the islets of Langerhans in the pancreas, which stimulates the secretion of insulin and leads to a decrease in the level of glucose and glycated hemoglobin in the blood.
Semaglutide also reduces the patient's energy intake by reducing appetite, food cravings, and changing food preferences to lower calorie diets.
Semaglutide pen works by mimicking the action of GLP-1, a natural hormone in the body. This action includes:
Through these combined mechanisms, semaglutide promotes long-term glycemic control and weight management.
Semaglutide pen 5 mg is usually administered subcutaneously once weekly. The dosage is adjusted by the doctor based on the patient's needs. It is essential to follow the doctor's instructions and refrain from experimenting on your own.
General:
Less common but serious:
People with a history of thyroid tumors or MEN-2 syndrome should avoid taking this drug.
patients with a personal or family history of thyroid cancer;
persons with pancreatitis or gallbladder disease;
pregnant and lactating women;
persons not under constant medical supervision.
| Characteristics | |
| Active ingridient | Semaglutide |
| Shipping | |
| Warehouse | B2G1 |
There are no reviews for this product.